The current role of model-based drug development

被引:15
|
作者
Suryawanshi, Satyendra [1 ]
Zhang, Liping [2 ]
Pfister, Marc [2 ]
Meibohm, Bernd [1 ]
机构
[1] Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Coll Pharm, Memphis, TN 38163 USA
[2] Bristol Myers Squibb Res & Dev, Princeton, NJ USA
关键词
drug development; modeling; pharmacodynamics; pharmacokinetics; simulation; CLINICAL-TRIAL SIMULATION; QUANTITATIVE PHARMACOLOGY; LABELING DECISIONS; DARBEPOETIN-ALPHA; INTEGRATION; DISEASE; BIOMARKERS; APPROVAL; IMPACT;
D O I
10.1517/17460441003713470
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Current drug discovery and development programs are under growing scrutiny for low productivity and escalating costs. Model-based drug development (MBDD) has been recognized as a promising tool to address some of the related challenges. Areas covered in this review: This review introduces the concept of MBDD and the associated quantitative pharmacology-based iterative 'learn and confirm' paradigm in the drug discovery and development process to provide concise information for rational decision making. It summarizes the evolving role of MBDD in drug development programs and outlines the full armamentarium of modeling and simulation approaches utilized to facilitate its application. What the reader will gain: Different aspects and applications of MBDD are introduced to the reader and illustrated in prime examples. The reader is provided with an understanding of potential applications of MBDD in drug development as well as the associated limitations and challenges in its implementation. Take home message: MBDD is a tool that is increasingly used throughout the drug discovery and development continuum to support fast and rationale decision making and has thereby the potential to accelerate and increase the cost-effectiveness of the drug development process.
引用
收藏
页码:311 / 321
页数:11
相关论文
共 50 条
  • [1] Model-based drug development
    Lalonde, R. L.
    Kowalski, K. G.
    Hutmacher, M. M.
    Ewy, W.
    Nichols, D. J.
    Milligan, P. A.
    Corrigan, B. W.
    Lockwood, P. A.
    Marshall, S. A.
    Benincosa, L. J.
    Tensfeldt, T. G.
    Parivar, K.
    Amantea, M.
    Glue, P.
    Koide, H.
    Miller, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (01) : 21 - 32
  • [2] Model-based drug development: application of modeling and simulation in drug development
    Kim T.H.
    Shin S.
    Shin B.S.
    Journal of Pharmaceutical Investigation, 2018, 48 (4) : 431 - 441
  • [3] An aide memoire for model-based drug development
    Boutouyrie-Dumont, B.
    BIOMARKERS IN MEDICINE, 2013, 7 (01) : 89 - 89
  • [4] Model-based drug development applied to oncology
    Barrett, Jeffrey S.
    Gupta, Manish
    Mondick, John T.
    EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (02) : 185 - 209
  • [5] Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development
    Milligan, P. A.
    Brown, M. J.
    Marchant, B.
    Martin, S. W.
    van der Graaf, P. H.
    Benson, N.
    Nucci, G.
    Nichols, D. J.
    Boyd, R. A.
    Mandema, J. W.
    Krishnaswami, S.
    Zwillich, S.
    Gruben, D.
    Anziano, R. J.
    Stock, T. C.
    Lalonde, R. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (06) : 502 - 514
  • [6] Pharmacodynamic Biomarkers in Model-Based Drug Development in Oncology
    Keizer, Ron J.
    Schellens, Jan H. M.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    CURRENT CLINICAL PHARMACOLOGY, 2011, 6 (01): : 30 - 40
  • [7] Model-Based Drug Development: The Road to Quantitative Pharmacology
    Liping Zhang
    Vikram Sinha
    S. Thomas Forgue
    Sophie Callies
    Lan Ni
    Richard Peck
    Sandra R. B. Allerheiligen
    Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33 : 369 - 393
  • [8] Model-based drug development: The road to quantitative pharmacology
    Zhang, Liping
    Sinha, Vikram
    Forgue, S. Thomas
    Callies, Sophie
    Ni, Lan
    Peck, Richard
    Allerheiligen, Sandra R. B.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2006, 33 (03) : 369 - 393
  • [9] Model-Based Drug Development in Oncology: What's Next?
    Bruno, R.
    Mercier, F.
    Claret, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (04) : 303 - 305
  • [10] Applications of Model-Based Meta-Analysis in Drug Development
    Phyllis Chan
    Kirill Peskov
    Xuyang Song
    Pharmaceutical Research, 2022, 39 : 1761 - 1777